NON-AQUEOUS INJECTABLE COMPOSITION FOR SUSTAINED RELEASE OF BUPRENORPHINE AND USE THEREOF

The present invention discloses a sustained release non-aqueous injectable composition of buprenorphine, its metabolite, its prodrug, or its salt thereof for the treatment of moderate-to-severe pain and opioid dependence. The non-aqueous injectable composition includes one or more biocompatible non-aqueous solvents, one or more release retarding agents, one or more surfactants, one or more biodegradable polymers and one or more stabilizers. The buprenorphine composition of the present invention delivers buprenorphine over a period of about one week to 12 weeks after single administration which leads to better patient compliance by reducing the daily dose administration of buprenorphine. The present invention also provides an injectable composition with potentially less pain due to the use of smaller gauge needles wherein the suitable gauge of needle may be 23 gauge to 30 gauge with a length of 8 to 30 mm. The preferred size of needle is 25 to 30 gauge..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 07. Sept. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

SAXENA KUNAL [VerfasserIn]
SAXENA NAVIN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-09-07, Last update posted on www.tib.eu: 2023-09-25, Last updated: 2023-09-29

Patentnummer:

AU2022222600

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA00238731X